1. Home
  2. CASI

CASI

CASI Pharmaceuticals Inc.

Logo CASI Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-24-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

Founded: 1991 Country:
United States
United States
Employees: N/A City: N/A
Market Cap: 33.5M IPO Year: 1996
Target Price: $12.00 AVG Volume (30 days): 205.5K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.02 EPS Growth: N/A
52 Week Low/High: $1.85 - $8.48 Next Earning Date: 05-15-2024
Revenue: $33,879,000 Revenue Growth: -21.41%
Revenue Growth (this year): 100.27% Revenue Growth (next year): -11.05%

Share on Social Networks: